News | June 10, 2025
Glenmark Pharmaceuticals to launch DCGI-approved BRUKINSA in India for treatment of hematological malignancies
Globally, BRUKINSA is approved in more than 70 countries
Globally, BRUKINSA is approved in more than 70 countries
This project builds on a previous joint funding agreement between CARBOGEN AMCIS and the same customer in April 2021
Oxcarbazepine ER Tablets (RLD Oxtellar XR) had estimated annual sales of US$ 206 million in the US (IQVIA MAT April 2025)
46% reduction in the risk of disease progression or death, and 27% reduction in the risk of death, in an aggressive cancer type with limited survival and few treatment options
Launches FSSAI’s inclusive campaign to stop obesity with multilingual, sign language outreach and multi-platform media engagement under Eat Right India programme
Enhanced alignment to better serve customers across the entire drug development lifecycle under the Fujifilm Life Sciences brand umbrella with the tagline Partners for Life
The 16,000-square-foot expansion enhances DuPont’s global sterile operations
AMPLIFY Phase III trial results demonstrated statistically significant and clinically meaningful improvement in progression-free survival for Calquence combinations
If approved, linerixibat could address high unmet medical need of patients living with cholestatic pruritus (relentless itch) and related sleep interference
The NPPA has capped prices for 41 drug combinations including diabetes, cholesterol, and sleep disorder treatments
Subscribe To Our Newsletter & Stay Updated
